{ "kind": "framework", "value": "forest-plot", "collectionKey": "slides:framework:forest-plot:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 8, "page": 1, "pageSize": 24, "pageCount": 1, "rows": [ { "docId": "019de074-1527-7308-955d-4c9eab2bbacb", "docSlug": "e812f3c221148b99b15c4527dea8f94b", "documentTitle": "argenx SE | Results Presentation Deck | 15 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "comparison_table", "function": "analyze_data", "notes": "The chart displays point estimates and 95% confidence intervals for the treatment effect across multiple clinical and demographic categories.", "imagePath": null, "matchCount": 1, "evidence": "Standard statistical visualization for subgroup analysis with confidence intervals", "slideHref": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/11", "deckHref": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchorHref": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-11", "loopMatches": [ { "to": 11, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "23e75dc1-17d4-4126-ac6f-02b66dffe107", "evidence": "Sustained Platelet Count Response by Subgroup Analysis.", "position": 0, "objective": "Show subgroup analysis favoring efgartigimod", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de072-a06b-75fe-abfc-06d6c9b36d69", "docSlug": "20a8e4b0fa87449fed1951c46c728b45", "documentTitle": "argenx SE | Results Presentation Deck | 21 slides", "authorId": "argenx-se", "authorName": "argenx", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-05-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "key_takeaways", "function": "analyze_data", "notes": "Forest plot showing 95% confidence intervals for treatment effect across multiple clinical variables.", "imagePath": null, "matchCount": 1, "evidence": "Visual representation of subgroup analysis with confidence intervals", "slideHref": "/slides/019de072-a06b-75fe-abfc-06d6c9b36d69/11", "deckHref": "/decks/019de072-a06b-75fe-abfc-06d6c9b36d69", "deckAnchorHref": "/decks/019de072-a06b-75fe-abfc-06d6c9b36d69#slide-11", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de072-1970-7036-9d15-9ffed6304914", "docSlug": "3db8307bc8c7b92a71fc075519a1ccaf", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 35 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-02-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "comparison_table", "function": "analyze_data", "notes": "The slide uses a forest plot to visualize HRs and 95% CIs for multiple clinical subgroups.", "imagePath": null, "matchCount": 1, "evidence": "Standard clinical trial subgroup analysis visualization", "slideHref": "/slides/019de072-1970-7036-9d15-9ffed6304914/14", "deckHref": "/decks/019de072-1970-7036-9d15-9ffed6304914", "deckAnchorHref": "/decks/019de072-1970-7036-9d15-9ffed6304914#slide-14", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-f579-76ad-bea5-b34da2c83a75", "docSlug": "563487226462eb4ab63630eb9b74a5cf", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 42 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-01-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 40, "slideType": "appendix_data", "function": "analyze_data", "notes": "The plot visualizes subgroup analysis for a clinical trial, indicating treatment efficacy across different patient demographics and clinical characteristics.", "imagePath": null, "matchCount": 1, "evidence": "Standard clinical trial subgroup analysis visualization", "slideHref": "/slides/019de071-f579-76ad-bea5-b34da2c83a75/40", "deckHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75", "deckAnchorHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75#slide-40", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-1718-756f-8ae4-37f1cf0d16ed", "docSlug": "2a95ead0d9ef429fb8fb8c2cc4a7d704", "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 52 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-06-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "comparison_table", "function": "analyze_data", "notes": "Standard forest plot used in clinical trial reporting.", "imagePath": null, "matchCount": 1, "evidence": "Standard clinical trial visualization for subgroup analysis", "slideHref": "/slides/019de075-1718-756f-8ae4-37f1cf0d16ed/17", "deckHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed", "deckAnchorHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed#slide-17", "loopMatches": [ { "to": 25, "from": 15, "name": "Before After", "slug": "21-before-after", "bestFor": "Product demos, process improvements, ROI justification", "matchId": "b41eaf1b-437d-4b91-9988-0e6fb0f284a8", "evidence": "The deck presents data and results from various trials, showcasing the company's progress in oncology", "position": 1, "objective": "What are the benefits of AstraZeneca's pipeline?", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "confidence": 0.7, "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison" } ], "arcBeatMatches": [ { "to": 25, "from": 15, "beatId": "ba7e7aa9-525b-4e2a-a4f1-214ecf8f098d", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "The deck presents data and results from various trials, showcasing the company's progress in oncology", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-2e43-774b-aad6-58a03a29d59d", "docSlug": "207557819f8810b573d3e2a3179a9bac", "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 55 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "comparison_table", "function": "analyze_data", "notes": "Forest plot showing hazard ratios for Imfinzi vs comparator across clinical subgroups.", "imagePath": null, "matchCount": 1, "evidence": "Visual representation of hazard ratios and confidence intervals across subgroups", "slideHref": "/slides/019de077-2e43-774b-aad6-58a03a29d59d/27", "deckHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d", "deckAnchorHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d#slide-27", "loopMatches": [ { "to": 35, "from": 22, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e1d82b9f-ab34-4351-be54-5e9df327f1c4", "evidence": "The document highlights the high unmet need and presents NIAGARA as a solution.", "position": 0, "objective": "What is the cost of not addressing the unmet need in muscle-invasive bladder cancer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 30, "from": 26, "beatId": "617689da-c69b-43c7-8222-b2a08def2699", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents the positive results of the NIAGARA trial.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-2e43-774b-aad6-58a03a29d59d", "docSlug": "207557819f8810b573d3e2a3179a9bac", "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 55 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "comparison_table", "function": "analyze_data", "notes": "Forest plot showing hazard ratios with 95% confidence intervals for multiple clinical subgroups.", "imagePath": null, "matchCount": 1, "evidence": "Standard clinical trial subgroup analysis visualization", "slideHref": "/slides/019de077-2e43-774b-aad6-58a03a29d59d/29", "deckHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d", "deckAnchorHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d#slide-29", "loopMatches": [ { "to": 35, "from": 22, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e1d82b9f-ab34-4351-be54-5e9df327f1c4", "evidence": "The document highlights the high unmet need and presents NIAGARA as a solution.", "position": 0, "objective": "What is the cost of not addressing the unmet need in muscle-invasive bladder cancer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 30, "from": 26, "beatId": "617689da-c69b-43c7-8222-b2a08def2699", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents the positive results of the NIAGARA trial.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 16, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The chart uses a vertical dotted line at 0.2 to denote a clinical efficacy threshold.", "imagePath": null, "matchCount": 1, "evidence": "Visual representation of mean values with 95% confidence intervals across multiple cohorts.", "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/16", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-16", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 14, "beatId": "7f5902f2-01bd-4712-8ad0-4cf1f9223757", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 14-19 present results from the EnACT study", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }